Litvinchuk et al., 2024), oligodendrocyte myelination impairment (Blanchard et al., 2022), lowered vascular integrity (Montagne et al., 2021), mitochondrial dysfunction (Schmukler et al., 2020) and pathological interaction with Tau and A, many of which have been covered in numerous reviews (Blumenfeld et al., 2024
The concentration values below LLOQ were censored and treated as any value less than the LLOQ value
What quality control considerations are important for these peptide preparations
Retatrutide has one of the longest plasma half-lives on this peptide half-life chart at approximately 6 days, followed closely by Semaglutide at roughly 7 days and Tirzepatide at about 5 days
The metabolic context matters